Intravitreal Autologous Bone Marrow CD34+ Cell Therapy for Ischemic and Degenerative Retinal Disorders: Preliminary Phase 1 Clinical Trial Findings [Clinical Trials]

Conclusions. Intravitreal autologous BM CD34+ cell therapy appears feasible and well tolerated in eyes with ischemic or degenerative retinal conditions and merits further exploration. (ClinicalTrials.gov number, NCT01736059.)

http://www.iovs.org/cgi/content/full/56/1/81?rss=1

Source: Investigative Ophthalmology - January 6, 2015 Category: Opthalmology Authors: Park, S. S., Bauer, G., Abedi, M., Pontow, S., Panorgias, A., Jonnal, R., Zawadzki, R. J., Werner, J. S., Nolta, J. Tags: Clinical Trials Source Type: research